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Abstract
Previous studies have demonstrated that repeated administration of 17βestradiol (E-2) at a dose of 1mg/kg to both (SWR x NZB)F1 (SNF1) mice and
(DBA x BALB/c)F1(DBF1) mice resulted in significantly decreased survival and
increased appearance of lupus nephritis pathology. However, the ways in which
estrogen modulates immune responses has yet to be fully understood, specifically
in regard to modulations in TH1 and TH2 cytokine profile. Various studies have
reported the presence of two estrogen receptors (ER), α and β, which have been
found to be constitutively expressed in many immune cells. In the present project,
ER chimeric alpha knockout (αERKO), beta knockout (βERKO) and double
knockout (αβERKO) as well as wild type(WT) mice were injected monthly with
β-estradiol 17-valerate (E-2) at 1mg/kg. Control mice of each type received oil
vehicle only. Results showed that TH1 cytokine production by cells from WT
mice was suppressed by E-2 administration, although IFN-γ production was
increased in cells from βERKO mice treated with estrogen compared to those
treated with oil vehicle. TH2 cytokine production was increased in cells from WT
mice treated with estrogen compared to controls. Increases in the production of
anti-double stranded DNA antibodies were also observed in cells from αERKO
mice. These observations suggest a role for differences in ER-α and ER-β
expression in E-2 induced modulation of immune responses, including
autoimmune diseases like Systemic Lupus Erythematosus (SLE).
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INTRODUCTION
According to one study, it is estimated that approximately 5 percent of
populations in Western countries is affected by various autoimmune diseases (1).
The immune system is essential in the recognition of and distinction between self
and non-self entities. A typical immune system only generates a humoral and/or
cellular response to non-self such as pathogens, bacteria, antigens etc. However,
in some cases the immune system may recognize an individual’s own cells and
proteins as foreign, causing an autoimmune response. Contrary to what might
have been thought initially, autoimmunity is a normal process that is important in
clearing the body of certain pathological self cells (such as the prevention of
tumor metastasis) and cellular debris.
According to Davidson and Diamond (2001), autoimmune disease is
defined as a clinical syndrome caused by the activation of T or B cells, or both, in
the absence of an ongoing infection or other discernible cause. In other words,
autoimmune disease is caused by the failure of the proper functioning of the
body’s defense mechanisms, or a lack of tolerance of one’s own cells. There exist
two categories of autoimmune diseases. Organ-specific autoimmune diseases,
such as type 1 diabetes mellitus, are localized in specific tissues in the body.
Systemic diseases, such as systemic lupus erythematosus (SLE), have a
widespread effect on several tissue systems in the organism. In general, these
diseases are caused by, either changes in selection and regulation of T cells or B
cells, or aberrant reactions to particular self or foreign antibodies (1).
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While there are many factors that can cause autoimmune disease, genetic
susceptibility is suggested to play an important role in disease manifestation. This
has been supported by evidence of familial clustering and higher rates of
concordance for the diseases in monozygotic twins than in dizygotic twins.
Certain autoimmune diseases are thought to be caused, in major part, by mutation
in a single gene. Such is the case of autoimmune lymphoproliferative syndrome, a
disease with an autosomal dominant heredity pattern resulting from defects in the
Fas protein (1). Fas protein is essential in mediating apoptotic pathways in the
body and serves to down-regulate immune responses (1). The defect in the gene
for the Fas protein results in the organism’s inability to successfully perform
apoptosis, and therefore delete, activated immune cells that are reactive with self
antigens.
It is important to note, however, that not all individuals who possess this
single gene mutation will develop the disorder. There are many other factors that
interact to enhance one’s susceptibility to autoimmunity. In fact it has been
revealed that susceptibility to most autoimmune diseases results from the
stochastic or simultaneous affects of mutations in many genes. Thus there are
many susceptibility genes that contribute to the onset of disease in patients. For
example, there is evidence that the genes for the class I and class II HLA major
histocompatibility complex molecules, which are responsible for antigen
presentation by antigen presenting cells (APCs), in association with the tumor
necrosis factor α gene (TNF-α), are involved in most autoimmune diseases.
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Furthermore, many autoimmune diseases share common susceptibility genes,
predisposing individuals to a combination of diseases.
Although certain individuals possess genes that confer susceptibility to
disease, in many the onset of autoimmunity may be triggered by environmental
factors. Two categories of such factors can be distinguished: infectious and noninfectious agents. In the case of multiple sclerosis for instance, the manifestation
of the disease is primarily due to both T cell auto-reactivity to a peptide from the
auto-antigen myelin basic protein, and T cells with reactivity to peptides from the
Epstein-Barr virus, influenza virus type A, and human papillomavirus. A potential
explanation is that the onset of disease is initiated by a normal immune response
to a viral or bacterial infection, which is then sustained, even after elimination of
the threat, by T cell reactivity to autoantigens that are homologous or “mimic” the
foreign antigen.
Various studies have noted a significant sex difference in immune
responses to antigens. It appears that females in many species are seen to have
heightened immune responses and are more susceptible to autoimmunity (2, 3).
Particularly, in Systemic Lupus Erythematosus (SLE), we see a 9:1 ratio in
predominance of the disease in women as compared to men (6-7). There is also
evidence of the correlation between steroid hormone levels and the changes in
clinical manifestation of SLE, which is additionally enhanced during pregnancy
and the postpartum period (8-10). Male and female patients with SLE often have
abnormally high levels of estrogen (hyperestrogenic) and/or abnormally low
levels of androgen (testosterone) hypoandrogenic (11-13). This correlation is also
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reinforced by the higher incidence of the disease in patients with Klinefelter’s
syndrome (14, 15), which is a genetic disease of males that is characterized by a
variety of sex hormone abnormalities, including increased production of estrogen.
These data, therefore, point to a potential significant role of estrogen in the
gender-specific modulation of immune responses involved in autoimmunity.
Research done in the Gavalchin Lab using the (SWR x NZB) F1 (SNF1)
mouse model for the human autoimmune disease Systemic Lupus Erythematosus
(SLE) has provided a more direct evidence of the correlation between estrogen
levels and SLE. Specifically, repeated administration of 17β-estradiol (E-2) at a
dose of 1mg/kg to male (SWR x NZB)F1 ( SNF1) mice, which do not develop
lupus unlike SNF1 female mice, beginning at 7 weeks and then monthly thereafter
for another 4 months, resulted in significantly decreased survival, similar to that
of female SNF1 mice, compared to vehicle-treated male mice. By the 3rd dose
(about 20 weeks of age), there was a significant development of excess serum
protein in the urine (proteinuria), with an additional increase in autoantibodies
expressing a pathogenic biomarker for lupus, IdLNF1+, in the serum of E-2 treated
male SNF1 mice. IdLNF1-reactive T cells with a memory phenotype
(CD44+CD45-) had also increased significantly in E2-treated mice and were found
in the kidneys. Splenocytes from E-2 treated mice produced significantly more
Id540+ (a subset of IdLNF1+) IgG&M in vitro than splenocytes from control mice
when incubated with control T cells, which is evidence for the pathogenic role of
the Id LNF1-reactive T cells. Lastly, at 25 weeks of age, 80% of the estrogentreated mice had glomerular deposits of IdLNF1+ immunoglobulins (2). These
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results point to the interaction of estrogen with immune cells. However, the ways
in which estrogen modulates immune responses are still not yet well understood.
Key to this knowledge would be an understanding of how estrogen interacts with
its receptors. Two forms of estrogen receptors (ER), ERα and ERβ, have been
identified. Each of these receptor subtypes or isoforms have been found to be
normally expressed in immune cells (16-21).
Thus, the purpose of this research project was to further investigate the
influence of estrogen on autoimmunity, specifically in SLE. It has been suggested
that estrogen may act on helper T lymphocytes (TH), which are an essential part of
the normal immune response to antigens. Two types of TH cells are known: TH1
and TH2 cells, which are distinguished by the specific cytokines they produce.
TH1-type cytokines lead to pro-inflammatory responses in the host and while they
participate in the initiation of autoimmune responses, they are protective later in
disease. TH2-type cytokines are important in immunoglobulin production and
predominate in later disease (22). Experiments on male estrogen receptor (ER)
knockout mice that were administered estrogen (E-2) showed that the shifts from
TH2 to TH1 responses were protective while a TH2 response exacerbated
autoimmune disease (16-21). These results suggested that estrogen has a
differential effect in promoting TH1 and TH2 responses, as well as raise the
question of the importance of the ER in inducing these responses since CD4+ T
cells have been show to express ER. Consequently, the hypothesis that was tested
in this project was that exposure to estrogen will lead to modulation of immune
cells via interaction with the specific ERs that they express. To do this, we
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exposed male ERα, ERβ and ERαβ knockout chimeric mice to chronic doses of
estrogen with the aims of identifying the consequences of estrogen (E-2) exposure
in the numbers and functions of immune cells, in order to determine whether these
modulations resulted from the interaction of E-2 and ER expression.

MATERIALS AND METHODS

Derivation of ER deficient chimeric mice
Thirty C57 Black 6 (C57BL/6) male mice were placed on an acid water
regimen two days before irradiation to reduce nasal Pseudomonas infection. They
were then irradiated with a total of 1100 rads, distributed in two doses, with five
hours between the two irradiations. The day after irradiation, the mice were
reconstituted with cells from donor bone marrow prepared from either of four
types of male ER-deficient mice: wild type (WT), alpha knockout (αERKO), beta
knockout (βERKO) or double knockout (αβERKO or KO/KO) for the E-2
receptor. To prepare the donor cells, 2-3 mice of the appropriate ER genotype
were euthanized by CO2 asphyxiation. Their femurs and tibias were removed and
placed in a dish of sterile HBSS containing 5ml RPMI with 5% FBS. All muscle
was removed from the bones. The ends were cut off and the bone marrow was
flushed out using 5ml solution of RPMI with a syringe and a 25g needle. The
marrow was flushed into another dish containing HBSS and was passed through a
22g needle in order to break up the clumps. The mixture was then spun down and
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suspended in media. The cells were counted, and resuspended at a concentration
of 1x107 cells/mL.
Groups of seven irradiated recipient mice were reconstituted with 0.2 ml
(5x106) of the appropriate cell type by intravenous injection in the tail vein. Two
mice served as controls for irradiation and were not reconstituted. All mice were
maintained on acid water, with antibiotics for one month. Within ten days of
irradiation, the two control mice were moribund. This confirmed that the lethal
irradiation was successful.
Seven weeks after reconstitution, four mice from each group were injected
with E-2 (17 β-estradiol valerate-1 mg/kg) in oil and three mice were injected
with oil vehicle by bolus injection subcutaneously between the shoulder blades.
These injections were performed subsequently every month (4 weeks) for 5
months. Body weights were measured before each injection. This dosing regimen
elevated mouse serum E-2 level to the peak physiological serum E-2 level in
female mice of 150~200pg/ml (23). The level of E-2 was maintained for about 7
days and decreased to normal levels found in male mice 2 weeks after treatment.

Cell harvesting
Two weeks after the 5th injection of estrogen, the treated and control mice
were euthanized for experimental analysis. Body weight was recorded, and blood
was collected. Tissue from thymus, spleen and kidneys were harvested
individually from each mouse and cell suspensions were prepared in order to
determine specific phenotypes. Red blood cells were lysed by resuspending the
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cell suspension in 5mL TAC (tris-ammonium chloride), and the cells were
counted.

In vitro cytokine enzyme linked immunosorbent assay (ELISA)
Lymphocytes from individual ER chimeric mice from each treatment
group were cultured with Con A or idiopeptide aa62-73 (24-27). Cells and
supernatant were collected on day 3 for cytokine production and day 7 for
immunoglobulin production. Supernatants were frozen at -70º C until assays were
conducted. ELISA was used to measure Interleukins 2, 4, 10, 12, IFNγ, to identify
Th1/Th2-type cytokine shifts (R & D Diagnostics, e-Biosciences). Briefly, 96
well Nunc Maxisorp plates were coated with 50µl of the appropriate dilution of
anti-cytokine capture antibodies in 0.1M carbonate coating buffer pH 9.5 (IL-2,
IL-4, IFN-γ) or 0.2M phosphate coating buffer pH 6.5 (IL-10 and IL-12). Plates
were incubated overnight at 4 ºC, washed two times with PBS/0.05% Tween
(wash solution), and then blocked with 50 µl of the assay diluent (PBS/10%FBS
pH7) for 1 hour at room temperature (RT). The plates were then washed two
times, and cytokine standard and supernatant samples diluted 1:2 in assay diluents
were added to the wells. After an overnight incubation at 4 ºC, the plates were
washed three times with wash solution, and then 50µl of appropriately diluted
biotin-conjugated detection antibodies was added to the wells and incubated
overnight at 4 ºC. The plates were then washed four times, and 50µl strepavidinconjugated horseradish peroxidase (HRP), diluted 1:250 in assay diluent, was
added and incubated for 30 minutes at RT. Lastly, the plates were washed five
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times, and 50µl TMB substrate was added to each well. Color change
corresponding to bound antibody was monitored for 15-30 minutes at RT, and
then the reaction stopped by adding 50µl of H3PO4 to each well. The absorbance
was then read at 450nm. The concentration of each cytokine in the culture
supernatant was determined from a standard curve.

Table 1. Cytokine assays capture and detection antibody dilutions and standard
range.
Cytokines
Capture Antibody
Detection
Standard
Dilution
Antibody Dilution Range (pg/mL)
1:250
1:250
0-200
IL-2
1:250
1:250
0-500
IL-4
1:1000
1:500
0-2000
IL-10
1:250
1:250
0-100
IL-12
1:1000
1:500
0-1000
IFN-γ

In vitro immunoglobulin ELISA
For this assay, 96 well Immulon 1B plates were coated with 50µL per well
of single-stranded DNA (ssDNA or double-stranded DNA (dsDNA) at 5µg/mL in
1X SSC. The plates were incubated overnight at 4º C and were subsequently
washed 2 times with PBS/1%Tween and 2 times with PBS. The plates were
blocked with 50µL of PBS/1%Tween per well, incubated for an hour at RT and
washed as previously described. Then 50µL of each supernatant sample diluted
1:2 in PBS/0.1%Tween in duplicate, was added to the wells of the plate and
incubated overnight at 4º C. The plates were washed twice with PBS/1%Tween
and twice with PBS. Next 50µL of anti-goat IgM and IgG alkaline-phosphatase
conjugate in PBS/0.1% Tween (1/2000 dilution) was added to all of the wells.
The plates were incubated overnight at 4º C and washed as in previous steps.

10
Lastly, 50µL of substrate solution paranitrophenyl phosphate (PNPP) was added,
and allowed to develop until color change was apparent (approximately 30
minutes). Color development was then read at 405nm.

Statistical analyses
Data was analyzed by one-way ANOVA with post hoc comparisons by the
Student-Newman-Keuls multiple comparisons test. Differences in significance
will be considered at p <0.05.
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RESULTS

Effect of estrogen treatment on survival of WT and estrogen receptor-deficient
chimeric mice

All WT mice survived throughout the duration of the experiment.
Estrogen treated mice αERKO mice showed a lower survival rate than those that
were treated with oil. One out of four mice died during the third month of
injections. Mice from the βERKO estrogen treatment group also showed a lower
survival rate than those that were treated with oil. There was one death out of four
during the third month of injections. Additionally, estrogen-treated αβERKO mice
also had a lower survival rate, with half of the mice in this group moribund within
three months and four months of the experiment. This is in contrast with the
control αβERKO mice which all survived the duration of the experiment.

Table 2. Deaths of estrogen receptor-deficient chimeric mice. There were no
deaths among any of the oil treated ER chimeric mice, while 1-2 mice from each
E-2 treated ER KO chimera became moribund during the course of the injections.
Treatment Groups
WT + Oil
WT + E-2
αERKO + Oil
αERKO + E-2
βERKO + Oil
βERKO + E-2
αβERKO + Oil
αβERKO + E-2

Ratio of Death of Total Group
Number
0
¼
0
¼
0
¼
0
½
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Effect of estrogen treatment on body weights of WT and estrogen receptorreceptor
deficient chimeric mice

In general, oil treated (control) WT mice had higher body weights than the
αβERKO, αERKO
ERKO and βERKO
ERKO control mice. But estrogen treatment resulted in
lowered body weights in the WT and the ER
ER-deficient
deficient chimeras, compared to
controls (Figure 1).

E2 treatment effect on body weight
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Figure 1. Body weights of estrogen receptor-deficient
deficient chimeric mice. Body
weights were recorded before each estrogen injection at each time point for
estrogen treated (n=4) and control (n=3) ER
ER-chimeric mice.

a. WT mice
The weights of the wild
wild-type
type (WT) mice treated with estrogen were
significantly lower than the weights of the oil vehicle treatment group (p(p
value=0.014). Data showed that both groups averaged approximately the same
weight at the first injections (25g), bu
butt diverged from then on. At the final
injection, the WT oil
oil-treated
treated mice had an average weight of 32.3g (+/(+/ 1.9g) while
the estrogen-treated
treated group weighed an average of 29.6g (+/
(+/-2.1g),
2.1g), a difference of
2.7g.
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b. αβERKO mice
Data of body weights for the αβERKO mice showed that although the oiltreated mice maintained slightly higher weights than estrogen-treated mice
throughout the experiment, with the exception of the 5th injection, the weight
differences were not significant. At the 5th injection, the average body weight of
the αβERKO oil-treated mice was 5.7g higher than the estrogen-treated αβERKO
mice, but this was not significant.

c. αERKO mice
The weights of the oil-treated αERKO chimeric mice were significantly
higher that weights of estrogen-treated mice at later injections. On average, the
oil-treated mice weighed 2.9g (+/- 2.4) more than the estrogen-treated groups,
with the greatest significant difference of 5.6g (+/- 2.4) at the 5th time point (pvalue=0.01).

d. βERKO mice
The body weights of βERKO mice in both the oil and estrogen treatment
groups were similar weight until the 4th injection, when the estrogen-treated mice
showed a sharp decrease in body weight with a difference of 4.5g (+/- 2.5)
between two groups at the 5th injection. This difference in weight, although not
significant, persisted until the end of the study.
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Effects of E2 receptor expression in the modulation of Th1 Cytokine production
Cells from each estrogen receptor chimeric mice were harvested and
cultured with Con A or idiopeptide aa62-73, to determine the effects of ER
receptor expression on cytokine production. An enzyme-linked immunosorbent
assay (ELISA) was used to determine the relative amount of Th1 cytokines, IL-2,
IFN-λ, IL-12, produced in media alone, Con-A and aa62-73.

a. IL-2

Cytokine production in cells cultured in media alone
When cells were cultured in media alone, we found that there was no
significant difference in IL-2 production by cells from the oil and estrogen-treated
mice (Figure 2a). Interestingly, for the αERKO chimeric mice, the production of
IL-2 by cells from estrogen-treated mice was significantly higher than production
by cells from oil-treated mice (p=0.0038). There was no statistically significant
difference in IL-2 production by cells from either βERKO or αβERKO chimeric
mice, with or without estrogen treatment.
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Figure 2a. Production of interleukin 2 (IL
(IL-2)
2) cytokines by cells from ER
chimeric mice treated with estrogen and vehicle. Cells isolated from each
treatment group were cultured in media alone (blank), media containing Con-A
Con
mitogen. IL-22 cytokine production was meas
measured
ured by ELISA and expressed in
terms of optical density (OD) at 450nm.
*Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.

Con A–induced
induced cytokine production
Data showed a significantly higher production of Con
Con-A induced IL-2
IL in
the WT control group, compared to the estrogen
estrogen-treated
treated group (p =0.008) (Figure
2a).. Thus, it appeared that E
E-2 suppressed the production of IL-2
2 by the WT cells.
Comparison of the different knockout groups showed that estrogen treatment did
d
not result in significant differences in IL
IL-2
2 production compared to oil control
mice. Further, IL--2 production by cells from all of the knockout groups was
significantly higher than that produced by cells from WT mice.
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Peptide 62-73
73 induced cytokine production
In general, IL
IL-2
2 production was significantly higher in all estrogen-treated
estrogen
and oil control chimeric receptor mice regardless of ER expression when cells
were stimulated with peptide 62
62-73. Figure 2b shows a significantly higher
production of IL-22 in the WT control group, compared to the estrogen group
(p=0.04). Thus, similar to what we saw with Con
Con-A,
A, it appears that E-2
E
suppressed the production of aa62
aa62-73-induced IL-2
2 production in the WT cells.
Although IL-22 production was slightly higher for αβERKO
ERKO cells that for the other
ERKO chimeric mice, the differences between the knockout groups were not
statistically significant.

Figure 2b. Production of interleukin 2 (IL
(IL-2)
2) cytokines by cells from ER
chimeric mice treated with estrogen and vehicle. Cells isolated from each
treatment group were cultured in media alone (blank) and aa62
aa62-73
73 peptide
(100µg/mL). IL-22 cytokine production was measured by ELISA and expressed in
terms of optical density (OD) at 450nm.
* Indicates results of statistical significance (e.g. p-value<0.05)
value<0.05) were found.
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b. IFN-gamma

Cytokine production in cells cultured in media alone
Unstimulated ccells from WT mice treated with E-2
2 produced relatively
higher levels of IFN
IFN-γ compared to cells from WT mice treated with oil (p-value=
(p
0.018) (Figure 3a)
3a). Similar results were also seen for αERKO
ERKO and αβERKO
mice; however this increase was not significant. In contrast, IFN
IFN-γ production by
cells from βERKO
ERKO mice treated with oil was greater than that produced by cells
from mice that had been treated with E
E-2.

Figure 3a. Production of interferon
interferon-γ (IFN-γ)) cytokines by cells from ER
chimeric mice treated with estrogen and vehicle. Cells isolated from each
treatment group were cultured in media alone (blank) and media containing ConCon
A mitogen. IFN-γγ cytokine production was measured by ELISA and expressed in
terms of optical density (OD) at 450nm.
* Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.
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Con A-induced cytokine production
Overall, Con-A stimulated cells showed higher productions of IFN-γ
compared to cells that were cultured in media alone or with peptide 62-73 (Figure
3a). Production by cells from WT mice treated with oil was slightly higher than
that produced by WT mice treated with E-2; however this increase was not
statistically significant. There was no difference in IFN-gamma production by
cells from the oil or estrogen treated αERKO mice. Data showed a higher
production of the cytokine by cells from the βERKO E-2 treated group as opposed
to cells from the βERKO control group (p-value=0.018). IFN-gamma levels
produced by cells from either the oil or the E-2 treated βERKO group were also
higher than those observed for any of the other WT or receptor knockout groups.
Finally, while the amount of IFN-γ produced by cells from the αβERKO control
group was higher than that produced by cells in the E-2 treated group, this
difference was not statistically significant.

Peptide 62-73 induced cytokine production
Production of IFN-γ by cells from WT mice treated with E-2 stimulated
with peptide 62-73 was greater than that produced by cells from WT mice treated
with oil (p-value=0.018) (Figure 3b). In general, however, IFN-gamma
production by cells from WT mice treated with oil was higher than levels
produced by cells from αERKO and βERKO chimeric mice, but similar to that
produced by cells from αβERKO mice. Further, cells from αβERKO chimeric
mice treated with E-2 produced slightly higher levels of IFN-γ compared to cells
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from αβERKO
ERKO chimeric oil
oil-treated control mice, while no
o effect was seen in the
αERKO and βERKO mice.

Figure 3b. Production of interferon
interferon-γ (IFN-γ)) cytokines by cells from ER
chimeric mice treated with estrogen and vehicle. Cells isolated from each
treatment group were cultured in media alone (alone) and media containing
aa62-73
73 peptide (100
(100µg/mL). IFN-γ cytokine production was measured by ELISA
and expressed in terms of optical density (OD) at 450nm.
* Indicates results of statistical significance (e.g. p-value<0.05)
value<0.05) were found.

c. IL-12

Cytokine production in cells cultured in media alone
Unstimulated cells from WT mice treated with E
E-2
2 displayed greater
production of IL-12
12 than cells from WT mice treated with oil, although
alth
this
difference was not statistically significant (Figure 4a).. Cells from αERKO
α
mice
showed no significant differences in IL
IL-12
12 production; however, significant
differences were seen for cells from the βERKO
ERKO treatment groups. Cells from E-2
E
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treated βERKO
ERKO chimeric mice produced more IL
IL-12
12 than cells from the oiloil
treated βERKO
ERKO control mice (p
(p-value=0.01).

Figure 4a. Production of interleukin 12 (IL
(IL-12)
12) cytokine by cells from ER
chimeric mice treated with estrogen and vehicle. Cells isolated from each
treatment group were cultured in media alone (blank) and media containing ConCon
A mitogen. IL-12
12 cytokine production was measured by ELISA and expressed in
terms of optical density (OD) at 450nm.
* Indicates results of statistical ssignificance (e.g. p-value<0.05)
value<0.05) were found.

induced cytokine production
Con A-induced
IL-12
12 production in response to Con was increased in cells from WT mice
treated with E-22 compared to that produced by cells from WT mice treated with
oil. On the other hand, cells from αERKO mice treated with E-2
2 produced lower
levels of IL-12
12 than cells from the αERKO oil control mice, but these
hese results were
not statistically significant. Cells from αβERKO
ERKO mice treated with estrogen
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produced significantly less IL
IL-12 than the controls (p-value=0.03).
value=0.03). No significant
differences were observed for βERKO mice.

Figure 4b. Production of interleukin 12 (IL
(IL-12)
12) cytokine by cells from ER
chimeric mice treated with estrogen and vehicle. Cells isolated from each
treatment group were ccultured
ultured in media alone (blank) and media containing
aa62-73
73 peptide (100
(100µg/mL). IL-12
12 cytokine production was measured by ELISA
and expressed in terms of optical density (OD) at 450nm.
* Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were
wer found.

Peptide 62-73
73 induced cytokine production
IL-12
12 production in WT cells stimulated with peptide 62-73
73 was slightly
higher than for the other receptor chimera groups, with cells from βERKO
β
E-2treated group producing the lowest levels (Figure 4b).. Cells from WT mice
treated with E-22 and stimulated with peptide 62 produced significantly higher
levels of IL-12
12 compared to cells from mice treated with oil (p
(p-value=0.02).
value=0.02). No
significant differences in IL
IL-12 production by cells from oil or E--2 treated
αERKO and βERKO
ERKO mice were observed. However, we did note significant
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differences for αβERKO mice. Cells from E-2 treated αβERKO chimeric mice
produced lower levels of IL-12 compared to cells from αβERKO mice treated
with oil (p-value=0.007).

Effects of E2 receptor expression on the modulation of Th2 cytokine production
Cytokine ELISA was used to determine the relative amount of Th2 cytokines,
IL-4 and IL-10, produced by cells from estrogen or oil treated WT or ER chimeric
mice cultured in media alone, or with Con-A or aa62-73.

a. IL-4

Cytokine production in cells cultured in media alone
There was no significant difference in IL-4 production by unstimulated
cells from the WT oil and estrogen-treated mice, although IL-4 levels in the E-2
treated mice were slightly higher (Figure 5a). There was also no significant
difference in IL-4 production by cells from αERKO and αβERKO chimeric mice.
However, cells from βERKO chimeric mice treated with estrogen produced
significantly less IL-4 than cells from oil-treated mice (p-value= 0.006).
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Figure 5a. Production of interleukin 4 (IL
(IL-4)
4) cytokine by cells from ER
chimeric mice treated with estrogen and vehicle. Cells isolated from each
treatment group were cultured in media alone (blank) and media containing ConCon
A mitogen. IL-4 cytokine production was measured by ELISA and expressed in
terms of optical density (OD) at 450nm.
* Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.

induced cytokine production
Con A-induced
Significantly higher levels of Con A-induced IL-4
4 were produced by cells
from WT mice treated with estrogen compared to that produced by cells from the
oil treated control group (p
(p-value=0.025) (Figure 5a). In the βERKO chimeric
mice however, the cells from mice that had been treated with estrogen produced
less IL-44 than cells from oil
oil-treated mice (p-value=0.002).
value=0.002). Comparison of the
αERKO and αβERKO
ERKO groups showed no significant difference in IL-4
IL production
by cells from control and E
E-2 treated mice.
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Peptide 62-73
73 induced cytokine production
There were no significant differences in peptide 62
62-73
73 induced IL-4
IL
production by cells from oil or estrogen
estrogen-treated
treated mice for WT or any of the ER
receptor knockout chimeras (Figure 5b).

Figure 5b. Production of interleukin 4 (IL
(IL-4)
4) cytokine by cells from ER
chimeric mice treated with estrogen and vehicle. Cells isolated from each
treatment group were cultured in media alone (blank) and media containing
aa62-73
73 peptide (100
(100µg/mL). IL-4 cytokine production was measured by ELISA
and expressed in terms of optical density (OD) at 450nm.
* Indicates results of sstatistical significance (e.g. p-value<0.05)
value<0.05) were found.
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b. IL-10

Cytokine production in cells cultured in media alone
IL-10
10 production by cells from WT mice treated with E
E-2,, and culture in
media alone, was greater than that by cells from WT oil treated control mice, but
this difference was not statistically significantly different (Figure 6a).
6a) Estrogen
treatment of βERKO
ERKO mice resulted in the production of significantly lower levels
of IL-10
10 than their oil control counterparts (p
(p-value=0.001). This
is was also seen in
the αβERKO
ERKO mice (p
(p-value=0.002). In general, cells from βERKO
ERKO mice produced
lower levels of IL
IL-10 compared to the WT, αERKO and αβERKO
ERKO groups.

Figure 6a. Production of interleukin 10 (IL
(IL-10)
10) cytokine by cells from ER
chimeric mice treated
reated with estrogen and vehicle. Cells isolated from each
treatment group were cultured in media alone (blank) and media containing ConCon
A mitogen. IL-10
10 cytokine production was measured by ELISA and expressed in
terms of optical density (OD) at 450nm.
* Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.
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Con A-induced cytokine production
Cells from WT mice treated with E-2 and cultured in Con-A produced
higher levels of IL-10 compared to WT control mice; however this difference was
not statistically significantly different (Figure 6a). In general, cytokine levels
produced by cells from the oil or E-2 treated WT were higher than levels
produced by cells from the other ER chimeric mice. This difference was
particularly significant when compared to IL-10 levels produced by cells from
βERKO chimeric mice (p-value=3.78x10-11). Cells from αERKO mice treated
with E-2 produced significantly lower levels of IL-10 compared to cells from
control αERKO (p-value=0.001). The same trend was seen in cells from βERKO
mice (p-value=7.0x10-4) and αβERKO mice (p-value=0.005). In general, cells
from βERKO mice in both estrogen and oil treatment groups produced lower
levels of IL-10 than cells from the WT, αERKO and αβERKO groups. Cells from
αβERKO mice treated estrogen or oil also produced greater amounts of cytokine
than αERKO and more significantly βERKO cells (p-value=4.42x10-9).
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Figure 6b. Production of interleukin 10 (IL
(IL-10)
10) cytokine by cells from ER
chimeric mice treated with estro
estrogen and vehicle. Cells isolated from each
treatment group were cultured in media alone (blank) and media containing
aa62-73
73 peptide (100
(100µg/mL). IL-10
10 cytokine production was measured by ELISA
and expressed in terms of optical density (OD) at 450nm.
* Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.

Peptide 62-73
73 induced cytokine production
Production of IL
IL-10
10 by cells from WT mice treated with E-2,
E and
stimulated with peptide 62
62-73, was greater, although not significantly,
significantl than levels
of IL-10
10 produced by the WT control (Figure 6b).. In general, peptide 62-73
62
induced IL-10
10 production by cells from WT mice, whether control or E-2
E treated,
were greater than the levels produced by cells from αERKO
ERKO and βERKO
β
chimeras, but simi
similar to that produced by cells from αβERKO
ERKO chimeras. Further,
Further
E-22 treatment of α
αERKO
ERKO chimeric mice resulted in the production of significantly
less IL-10
10 than cells from oil
oil-treated αERKO mice (p-value=0.02).
value=0.02). Similar results
were observed for cells from βERKO chimeras (p-value=1.0x10-44). On the other
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hand, cells from αβERKO mice treated with E-2 produced slightly higher levels
of IL-10 compared to αβERKO controls treated with oil.

Effects of ER expression on anti-single stranded DNA total immunoglobulin
(IgG and IgM) production
Cell culture supernatant from each group of estrogen receptor chimeric
mice was tested in an ELISA to determine the relative amount of anti-single
stranded DNA total IgG and IgM produced in the presence of media alone, LPS
or aa62-73.

a. Anti-ssDNA immunoglobulin production in cells cultured in media alone
Figure 7 shows the levels of anti-single stranded DNA antibodies (IgG and
IgM) produced by unstimulated cells in each ER knockout chimera group of mice.
In general, antibody production was highest for cells from αERKO mice and
lowest for cells from αβERKO mice. Differences in total immunoglobulin
production in WT estrogen-treated and control mice were recorded, however, they
were not of statistical significance. In contrast, there was a significant difference
in the production of total immunoglobulin by cells from both αERKO and
βERKO mice. Cells from αERKO mice treated with oil produced increased antissDNA antibodies compared to cells from αERKO mice treated with E-2 (pvalue=0.006). A similar trend was observed between control cells from βERKO
mice and cells from βERKO mice treated with E-2 (p-value=0.02). We also noted
a significant increase in antibody production by cells from αERKO mice treated

30
with E-22 compared to cells from WT mice treated with E-2 (p-value=3.1x10
value=3.1x10-3).
Cells from βERKO
ERKO mice treated with oil only also produced higher levels of
immunoglobulin compared to WT cells treated with oil (p
(p-value=3.4x10
value=3.4x10-4).

Figure 7. Effects of ER expression on anti
anti-single
single stranded DNA IgG and IgM
production by unstimulated cells from ER chimeric mice treated with estrogen
and vehicle. Cells isolated from each treatment group were cultured in media
alone (blank), media containing lipo
lipopolysaccharide
polysaccharide (LPS), and aa62-73
aa62
peptide.
Immunoglobulin production was measured by ELISA and expressed in terms of
optical density (OD) at 405nm.
* Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.

induced anti
anti-ssDNA immunoglobulin production
a. LPS-induced
Figure 8 compares levels of the anti
anti-single
single stranded DNA
immunoglobulin produc
produced by cells from the different ER knockout chimeric mice
groups stimulated with lipopolysaccharide (LPS). LPS is found in Gram negative
bacteria and is ann endotoxin that elicits strong immune responses in animals,
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including polyclonal production of immunoglobulin. We found an increase in
LPS-induced
induced immunoglobulin production for both oil and estrogen-treated
estrogen
cells
from αERKO
ERKO mice compared to cells from WT mice treated with oil and estrogen
(p-values=2.3x10--5 and 2.28x10-5 respectively). A similar trend was found in each
treatment group (oil or estrogen) for cells from βERKO and αβERKO mice
compared to the cells from WT mice, however results were lower for αβERKO
mice than for WT mice (p
(p-values=0.0004,
values=0.0004, 0.003, 0.0003 and 0.0003,
0.0003
respectively).

Figure 8. Effects of ER expression on anti
anti-single
single stranded DNA IgG and IgM
production by LPS
LPS-stimulated
stimulated cells from ER chimeric mice treated with
estrogen and vehicle
vehicle. Cells isolated from each treatment group were cultured in
media alone (blank), media containing lipopolysaccharide (LPS), and aa62-73
aa62
peptide. Immunoglobulin production was measured by ELISA and expressed in
terms of optical density (OD) at 405nm.
* Indicates
cates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.
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b. Peptide 62-73
73 induced anti
anti-ssDNA
ssDNA immunoglobulin production

Figure 9 shows the levels of anti
anti-single
single stranded DNA immunoglobulin
production by cells stimulated with the pathogenic peptide aa62-73
73 for each ER
knockout chimera treatment group. As expected, given that this is an antigenantigen
specific response, there was a general trend towards less antibody production in
aa62-73-stimulated
stimulated cells compared to unstimulated and LPS
LPS-stimulated
stimulated cells.
However, there was a significant increase in antibody production by cells from
αERKO
ERKO mice treated with estrogen compared to E
E-2
2 cells from WT mice (p(p
value=0.024). No differences were found between cells from oil treated control
mice, either WT or any of the ER knockout chimera. Decreased immunoglobulin
production by cells from αβERKO
ERKO mice was seen whether treated with oil or
estrogen compared to the WT groups (p
(p-values=0.001 and 0.004, respectively).
We did not find any differences in anti
anti-ssDNA
ssDNA production by cells from either oil
or estrogen treated βERKO chimeric mice.
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Figure 9. Effects of ER expression on anti-single stranded DNA IgG and IgM
production by aa62-73-stimulated cells from ER chimeric mice treated with
estrogen and vehicle. Cells isolated from each treatment group were cultured in
media alone (blank), media containing lipopolysaccharides (LPS), and aa62-73
peptide. Immunoglobulin production was measured by ELISA and expressed in
terms of optical density (OD) at 405nm.
* Indicates results of statistical significance (e.g. p-value<0.05) were found

Effects of ER expression in the modulation of anti-double stranded DNA total
immunoglobulin (IgG and IgM) production
Cells from each estrogen receptor chimeric mouse were harvested and an
ELISA was used to determine the relative amount of total anti-double stranded
DNA IgG and IgM produced in media alone, LPS and aa62-73.

a. Anti-dsDNA immunoglobulin production in cells cultured in media alone

Figure 10 shows the levels of anti-double stranded DNA antibodies (IgG
and IgM) produced by unstimulated cells for each ER knockout chimera group.
Generally, the production of anti-dsDNA antibodies was similar for all treatment
groups except for a statistically significant increase in the production of
antibodies by cells from αERKO chimeric mice treated with oil as compared to
cells from the WT mice (p-value=0.01).
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Figure 10. Effects of ER expression on anti-double
double stranded DNA IgG and IgM
production by unstimulated cells from ER chimeric mice treated with estrogen
and vehicle. Cells isolated from each treatment group were cultured in media
alone, media containing lipopolysaccharides (LPS), and aa62
aa62-73
3 peptide.
Immunoglobulin production was measured by ELISA and expressed in terms of
optical density (OD) at 405nm.
* Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.
b. LPS-induced
induced anti
anti-dsDNA immunoglobulin production

anti-double
double stranded DNA immunoglobulin
Figuree 11 compares anti
production by cells stimulated with LPS in the different ER knockout chimera
mice. The only significant difference found was an increase in anti-dsDNA
anti
immunoglobulin production in estrogen treated cells from βERKO
ERKO mice
compared to cells from βERKO mice treated with oil vehicle (p-value=0.035).
value=0.035).
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Figure 11. Effects of ER expression on anti
anti-double-stranded
stranded DNA IgG and
IgM production by aa62
aa62-73-stimulated
stimulated cells from ER chimeric mice treated with
estrogen and vehicle. Cells isolated from each treatment group were cultured in
media alone, media containing lipopo
lipopolysaccharides
lysaccharides (LPS), and aa62-73
aa62
peptide.
Immunoglobulin production was measured by ELISA and expressed in terms of
optical density (OD) at 405nm.
* Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.

c. Peptide 62-73
73 induced anti
anti-dsDNA
dsDNA immunoglobulin production

Figure 12 shows the levels of total anti
anti-double
double stranded DNA
immunoglobulin produced by cells stimulated with the pathogenic peptide aa62aa62
73 for each ER knockout chimeric group. We observed an increase in antibody
production
on by cells from αβERKO
ERKO estrogen treated chimeric mice compared to
cells from αβERKO
ERKO chimeric mice treated with oil (p
(p-value=0.01).
value=0.01). This trend was
also seen for cells from βERKO and αERKO
ERKO chimeric mice treated with estrogen
compared to oil treated cells, hhowever,
owever, these results were not significant.
Compared to the estrogen
estrogen-treated
treated cells from WT mice, cells from estrogen-treated
estrogen
αβERKO
ERKO chimeric mice had a higher production of the antibody (p-value=0.02).
(p
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Increased immunoglobulin production by cells from βERKO
O chimeras treated
with estrogen compared to cells from βERKO
ERKO mice treated with oil was also seen
(p-values=0.01).
values=0.01). There were no other significant differences seen.

E-2
2 Effects on Anti
Anti-dsDNA
dsDNA Production
0.2500
WT Control
WT Estrogen
AlphaKO Control
AlphaKO Estrogen
BetaKO Control
BetaKO Estrogen
KO/ KO Control
KO/ KO Estrogen

OD at 405nm

0.2000
0.1500
0.1000
0.0500
0.0000
Peptide 62
Treatment group

Figure 12. Effects of ER expression on anti
anti-double-stranded
stranded DNA production
by aa62-73-stimulated
imulated cells from ER chimeric mice treated with estrogen and
vehicle. Cells isolated from each treatment group were cultured in media alone,
media containing lipopolysaccharides (LPS), and aa62
aa62-73
73 peptide.
Immunoglobulin production was measured by ELISA and expressed in terms of
optical density (OD) at 405nm.
* Indicates results of statistical significance (e.g. pp-value<0.05)
value<0.05) were found.
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DISCUSSION

The higher occurrence of SLE in females versus males, as well as the
significant increase in the disease incidence in females after puberty, and the
fluctuation in disease severity throughout the menstrual cycle and pregnancy
suggests that sex hormones, specifically the female sex hormone estrogen, play an
important role in SLE and in autoimmunity (6, 7). This project sought to gain
further knowledge about the mechanisms by which estrogen mediates immune
responses that could explain the predilection of SLE in females. Particularly, we
investigated the significance of estrogen’s interactions with its various receptors
in modulating TH1 and TH2 immune response, since TH2-type cytokines
predominate in SLE. To address this question we examined cytokine and
autoantibody production in estrogen and oil vehicle-treated estrogen-receptor
knockout chimeric mice. In these mice, ER receptor expression was modulated
on immune cells only, so that these cells expressed only ER-α, ER-β, or no ER,
while non-immune cells expressed normal levels and types of all estrogen
receptor isoforms. The results in these mice were compared to results in WT
mice, which would express both ER. In addition, only male mice were used, in
order to obviate the effects of physiological levels of estrogen.

First, we looked at the effect of E-2 treatment on body weight. No body
weight differences were seen between the mice prior to estrogen treatment period.
E-2 administration of 1mg/kg monthly to male WT C57/black 6 mice and the
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three ER receptor knockout chimeric groups led to a decrease in survival rate, as
well as weight loss, compared to the control mice treated with oil vehicle only.
There was a lower survival and a significant decrease in body in estrogen treated
WT mice compare to the control oil-treated WT mice. The same trend was seen in
αERKO chimeric mice. Estrogen-treated mice in the βERKO and αβERKO
chimera groups also showed a large decrease in body weight, but only after the 4th
injection of E-2. The difference was particularly significant for the WT and
αERKO chimeric mice, suggesting a differential effect of α and β receptors in
mediating estrogen-induced cytokine production, with ER-α possibly playing a
greater role. Our observations for estrogen and oil treated WT mice are in
agreement with results reported by Feng et al. (28), which looked at the
development of lupus nephritis in αERKO mice and reported a significant
decrease in weight in WT mice treated with E-2. Other studies in both human and
animal models (29-32) have shown that estrogens serve to mobilize body fat and
induce the apoptosis of adipose tissue, thereby leading to a decrease in body
weight. This effect seems to be quite rapid; in fact, in the current study, body
weights of E-2 treated WT mice decreased significantly following the first and
second injections and remained lower than the control mice throughout the
duration of the experiment.
However, in contrast to our data, Feng et al. (28) did not observe a
significant difference in body weights in E-2-treated αERKO mice compared to
those treated with oil. However, in the previous work, the mice studied were ERα knockout mice and not ER-α knockout chimeric mice; the former would not
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express ER receptors on any cells or tissue while, the latter would be deficient in
ER expression on immune cells only, but other cells and tissues in the recipient
mice would express ER-α. This suggests that in our studies, estrogen’s effect in
the modulation of body weight was mediated by expression of ER-α on nonimmune cells.
Other research has shown varying effects of the sex hormone estrogen on
autoimmune disease manifestation. Some studies have shown that estrogen has
immunosuppressive effects in some organ-specific autoimmune diseases. One
study revealed that administration of E-2 to αERKO C57BL/6 mice resulted in the
suppression of the clinical signs of Experimental Autoimmune Encephalomyelitis
(EAE), an animal model of the autoimmune disease Multiple Sclerosis (MS) (33).
It has also been observed that the severity of multiple sclerosis in human
decreases as sex hormone levels increase during pregnancy, but this effect is
reversed postpartum due to alterations in sex hormones (34-36). Another study of
MS reported an enhanced stimulation of IL-10 secretion at pregnancy levels of E2, as well as an increase in IFN-γ in patients with the disease (37). On the other
hand, estrogen exposure has been shown to accelerate systemic autoimmune
diseases. Together, these findings have supported the important role of sex
hormones on immune responses and specifically autoimmune diseases.
One explanation for the differences in the response to estrogen in organspecific and systemic autoimmune diseases could be its role in cytokine
production. Estrogen stimulates the production of TH2 cytokines and promotes
interactions between T and B cells. It has also been reported that estrogen leads to
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increased secretion of IL-4, IL-5, IL-6 and IL-10 by TH2 lymphocytes (4, 38-40).
These cytokines stimulate the proliferation antibody-producing B cells. SLE
patients have increased levels of IL-6 and IL-10, which can be directly correlated
with clinical disease severity (39, 40). Increased levels of IL-4 in NZB/W and
MRL/lpr mice are also evident.
In our project, both TH1 and TH2 cytokine production was determined
using ELISA. Our findings show that when cells were cultured in media alone, in
the absence of any antigen or mitogen, IL-4 and IL-10 production by cells from
estrogen-treated WT mice was generally higher compared to cells from control
WT mice. Although these results were not statistically significant, they point to a
role for estrogen in TH2 cytokine production. Consistent with the findings of
Feng et al (28), which reported that serum levels of TH2 cytokines were not
increased in oil and estrogen-treated αERKO mice, we did not find differences in
cytokine production by cells from oil or estrogen-treated αERKO knockout
chimeric mice. This suggested that ERβ, which would be expressed in the ERα
KO chimeric mice, is likely not involved in estrogen-induced TH2 cytokine
production. Interestingly, our results showed a decreased in both IL-4 and IL-10
production by cells from estrogen-treated βERKO mice compared to oil-treated
βERKO mice, suggesting that estrogen-induced modulation of TH2 cytokines
production may be mediated by ER-α expression. Furthermore, this trend was
similar across all cytokines examined, both TH1 and TH2, as consistently lower
levels of cytokines were produced by βERKO cells treated with E-2 compared to
those treated with oil vehicle. Production of IL-4 by cells from both αERKO and
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αβERKO mice did not prove to be statistically significant. However, IL-10
production followed a similar trend for αβERKO as for βERKO cells, discussed
previously, with decreased production of the cytokine in αβERKO estrogentreated mice versus oil-treated mice. Taken together, these results point to the
importance of ER-α in estrogen-mediated TH2 cytokine production and a potential
role for ER-β in down-regulating this response, particularly with respect to IL-10
levels.
In response to Concanavalin A (Con A) WT mice treated with estrogen
produced higher levels of IL-4 and IL-10, although the increase in IL-10 levels
was not significant. We also observed a decrease in IL-4 and IL-10 production in
βERKO mice treated with estrogen compared to βERKO mice treated with oil.
This further supports the conclusion that estrogen-induced TH2 cytokine
modulation is not mediated by the ER-β isoform. Interestingly, a similar trend
was observed for IL-10 production by cells from αERKO mice. This suggests
that expression of both receptors is important in estrogen-induced TH2 cytokine
production after mitogen stimulation, with one or the other playing a more
predominant modulatory role depending on the specific cytokine.
We also looked at specific cytokine production in response to the
pathogenic idiopeptide, aa62-73. As expected from previous data (28), stimulation
of cells with the pathogenic IdLNF1 antigen resulted in an increase in TH2 cytokine
(IL-10) in cells from WT mice treated with estrogen compared to those treated
with oil only, although this difference was not statistically significant. This result
suggests that the pathogenic response in lupus nephritis may be enhanced directly
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by estrogen treatment. Interestingly, production was significantly decreased in
cells from αERKO mice treated with estrogen when compared to oil treated
αERKO mice. We found a similar trend for βERKO mice. These results suggest
that both ER receptors are important in estrogen-induced TH2 cytokine production
in response to pathogenic autoimmune peptides.
While in most autoimmune diseases, TH2 cytokines (IL-4, IL-10, and IL6) are important in later stages of disease, pro-inflammatory TH1 cytokines (IL-2,
IFN-γ, IL-12) are essential in initiation of pathology. Cytokine production in
male estrogen receptor (ER) knockout mice that were administered estrogen (E-2)
showed that the shifts from TH2 to TH1 responses were protective while a TH2
response exacerbated autoimmune disease (28). To further define the role of ER
in this process, we measured TH1 cytokine production in estrogen-treated ERKO
chimeric mice. Cells from αERKO chimeric mice treated with E-2 and cultured
in media alone produced higher levels of IL-2 and IFN-y (but not IL-12) than
those mice treated with oil. Interestingly, this result was different from that
observed by Feng et al, who found no differences in TH1 cytokine production by
cells from αERKO mice. However, differences in ER expression between the
two models, as discussed previously, may have contributed to this difference.
Conversely, as expected, Il-12 and IFN-γ production in WT mice was greater in
the estrogen treatment group compared to the oil treatment group. These data are
in agreement with previous studies that supported a role for IFN-γ in the onset,
but not later stages, of autoimmune disease (27).
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Mitogen-induced IL-2 and IFN-γ production by cells from WT estrogentreated mice was decreased compared to cells from WT oil-treated mice. From
this observation, it appears that TH1 cytokine production was suppressed by the
administration of estrogen in wild type mice, and this suppression may be
mediated by ER. This was further supported by the observation that there were no
differences in IL-2 production in any of the estrogen-treated ER knockout
chimeric mice. Interestingly, however, we found that IFN-γ production by cells
from estrogen-treated βERKO mice was greater compared to that produced by
cells from control βERKO mice. This, combined with the fact that no differences
were found for αERKO mice, suggests a role of ER-α in IFN-γ production. In the
case of IL-12 production, we noted that levels produced by cells from αERKO
and αβERKO estrogen-treated mice were decreased compared to the oil controls
of these groups, while the opposite results were seen for βERKO mice. Thus it
appears that ER-α expression may play a role in IFN-γ and IL-2 production but
not in IL-12 production. Additionally, because none of the cells from ER
knockout chimeric mice treated with estrogen showed any significant changes in
IL-2 production compared to the oil treatment groups, it is possible that both ERα and ER-β expression on immune cells play significant roles in promoting the
estrogen-induced TH1 cytokine production.
Finally, we found that in general, there was greater production of TH1
cytokines in the presence of the idiopeptide 62-73. While there was an increase in
IL-2 levels produced by cells from WT control mice compared to cells from
estrogen-treated mice, the opposite was observed for both IL-12 and IFN-γ, with
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cells from estrogen-treated mice producing higher levels of these cytokines. Our
results for IFN-γ were consistent with previous research (41), which reported an
increase in IFN-γ –producing cells in castrated female C57BL/6 mice, which was
ER-α and not ER-β dependent. However, with the exception of IL-12, we did not
find differences in TH1 cytokine production in αERKO, βERKO or αβERKO
mice. Thus our data suggests the importance of both ER-α and ER-β in estrogeninduced modulation of the pathogenic autoantibody response, with ER-α
expression being possibly more significant. Differences in the levels of
expression of each ER isoform, as observed by Feng et al (28) may also play a
role; in that study, ER-α was found to be expressed in a higher density than ER-β
on immune cells, which could explain why it may play a more significant role
than ER-β in modulating the immune response. Further, levels of ER were higher
in mice that were genetically susceptible to develop autoimmune disease relative
to MHC haploype-matched nonautoimmune mice. Finally, another study showed
that estrogen exposure directly activated T cells through the cell membrane ER-α
(42). Thus, differences in the numbers of each ER isoform expressed on the
immune cells of certain individuals could explain differences in T cell responses
to antigen, which could contribute to the development of autoimmune diseases. If
the levels of receptor expression between males and females also differ, this could
play a role in the predominance of autoimmune diseases in females as opposed to
their male counterparts.
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To further explore the role of ER expression in modulating the immune
response, particularly in terms of the development of autoimmunity, the effect of
ER-α and ER-β expression on estrogen-induced modulation of anti-single
stranded DNA and anti-double stranded DNA immunoglobulin levels was also
determined. Interestingly, we found that B cells from both αERKO and βERKO
mice treated with estrogen produced less anti-single stranded DNA than oiltreated mice. This same trend was seen in WT mice, although the difference was
not significant. Compared to cells from oil-treated WT mice, cells from oil-treated
βERKO mice produced significantly less immunoglobulin. Conversely, compared
to WT estrogen treated mice, cells from αERKO chimeras treated with estrogen
produced significantly greater levels of immunoglobulin. These data would
suggest a potential role for E-2 in modulating immunoglobulin production that
may involve estrogen interaction with both ER isoforms. The latter conclusion is
further supported by the observations that αERKO chimeric mice treated with E-2
produced greater amounts of anti-single stranded DNA immunoglobulin when
compared to cells from WT mice treated with E-2, as well as the fact that cells
from βERKO mice treated with oil produced higher levels of immunoglobulin
compared to WT cells treated with oil. These results suggest that ER-β expression
might have an up-regulating effect on E-2 mediated anti-single stranded DNA
immunoglobulin production, while the presence of ER-α expression would have a
down-regulating effect.
LPS-induced anti-single stranded DNA antibody production was increased
in both control and E-2 treated mice in all of the ERKO chimeric mice when
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compared to WT mice. This supports the idea that both ER-α and ER-β are
involved in anti-single stranded DNA immunoglobulin modulation by estrogen. In
the presence of IdLNF1 antigen (peptide 62-73), we found lower anti-single
stranded antibody production by cells from WT mice treated with estrogen when
compared to cells from WT mice treated with oil, suggesting that E-2 may
suppress the pathogenic B cell response to the antigen. We found that in the
presence of IdLNF1 antigen, as in the absence of it, there was a significant increase
in antibody production in cells from αERKO mice treated with estrogen compared
to E-2 cells from WT mice. However, no significant differences were found when
βERKO chimeric mice were compared to WT, suggesting that ER-β expression
was important in this response.
Previous studies have reported that the production of anti-double-stranded
DNA antibody is a specific biomarker for SLE in some patients (26). When cells
were cultured in media alone, we found a significant increase in production of
anti-DNA specific immunoglobulin by cells from αERKO mice treated with oil
when compared to cells from WT mice treated with oil, suggestive of the role of
ER-β expression in production of this antibody. No differences were found with
regard to E-2 treatment. However, LPS-induced anti-DNA specific
immunoglobulin production was increased when cells from βERKO E-2 mice
were compared to βERKO control mice , suggesting that in mitogen-induced
immunoglobulin production, ER-α may be involved.In the presence of IdLNF1 antigen, as expected from previous studies (28),
we found an increase in immunoglobulin production by cells from Wild Type
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mice after E-2 administration compared to control. This result points to a role of
E-2 in modulating pathogenic autoantibody production. We also found that antidouble stranded DNA antibody production by cells from αERKO estrogen treated
mice was decreased compared to αERKO oil-treated cells. The same trend was
seen in βERKO mice, suggesting that both ER-α and ER-β may be important in
this response. Significantly greater levels of total immunoglobulin was produced
by cells from estrogen treated αERKO and βERKO mice compared to WT mice
treated with estrogen. These data taken together suggest that ER-α and ER-β may
modulate pathogenic autoantibody-producing B cell responses. Our data also
showed that compared to the cells form oil-treated WT mice, cells from oiltreated αβERKO produced less ani-DNA antibody while the opposite was seen
when estrogen treated cells from these two groups were compared. This further
supports a role for estrogen in exacerbating the pathogenic B cell response.
In conclusion, our results provide further evidence supporting a critical
role for E-2 in triggering and/or modulating the development of autoimmune
lupus nephritis through its effect on cytokine production, since in general we saw
an increase in the levels of TH2 cytokines with estrogen treatment, as well as an
increase in levels of the TH1 cytokine IFN-γ. Results from our study also
provided evidence supporting a significant role for both ER-α and ER-β in the
development of theautoimmune disease cytokine and Ig profile, with ER-α have a
more significant effect. These findings support a role for estrogen and ER, and
may, in part, explain the increased incidence of autoimmune diseases in females.
Given our findings, the use of estrogen in contraceptives, hormone replacement
therapy and dietary supplements should continue to be evaluated.
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WRITTEN CAPSTONE SUMMARY

Project Description
Approximately 5 percent of the population in Western countries is affected
by various autoimmune diseases (1). The immune system is essential in the
recognition of and distinction between self and non-self entities. A typical
immune system only generates a humoral (antibody-specific) and/or cellular
response to non-self such as pathogens, bacteria, antigens etc. However, in some
cases the immune system may recognize an individual’s own cells and proteins as
foreign, causing an autoimmune response. Contrary to what might have been
thought initially, autoimmunity is a normal process that is important in clearing
the body of certain pathological self cells (such as the prevention of tumor
metastasis) and cellular debris.
According to Davidson and Diamond (2001), autoimmune disease is
defined as a clinical syndrome caused by the activation of T or B cells, or both, in
the absence of an ongoing infection or other discernible cause. In other words,
autoimmune disease is caused by the failure of the proper functioning of the
body’s defense mechanisms, or a lack of tolerance of one’s own cells. There exist
two categories of autoimmune diseases. Organ-specific autoimmune diseases,
such as type 1 diabetes mellitus, are localized in specific tissues in the body.
Systemic diseases, such as systemic lupus erythematosus (SLE), have a
widespread effect on several tissue systems in the organism. In general, these
diseases are caused by, either changes in selection and regulation of T cells or B
cells, or aberrant reactions to particular self or foreign antibodies (1).
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Various studies have noted a significant sex difference in immune
responses to antigens. It appears that females in many species are seen to have
heightened immune responses and are more susceptible to autoimmunity (2, 3).
Particularly, in Systemic Lupus Erythematosus (SLE), we see a 9:1 ratio in
predominance of the disease in women as compared to men (6, 7). There is also
evidence of the correlation between steroid hormone levels and the changes in
clinical manifestation of SLE, which is additionally enhanced during pregnancy
and the postpartum period (8-10). Male and female patients with SLE often have
abnormally high levels of estrogen (hyperestrogenic) and/or abnormally low
levels of androgen (testosterone) hypoandrogenic (11-13). This correlation is also
reinforced by the higher incidence of the disease in patients with Klinefelter’s
syndrome (14, 15), which is a genetic disease of males that is characterized by a
variety of sex hormone abnormalities, including increased production of estrogen.
These data, therefore, point to a potential significant role of estrogen in the
gender-specific modulation of immune responses involved in autoimmunity.
However, the ways in which estrogen modulates immune responses are still not
yet well understood. Key to this knowledge would be an understanding of how
estrogen interacts with its receptors. Two forms of estrogen receptors (ER) have
been identified, ERα and ERβ. Each of these receptor subtypes or isoforms have
been found to be normally expressed in immune cells (16-21). The purpose of this
research project was to further investigate the influence of estrogen on
autoimmunity, specifically in SLE. It has been suggested that estrogen may act on
helper T lymphocytes (TH), which are an essential part of the normal immune
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response to antigens. Two types of TH cells are known: TH1 and TH2 cells, which
are distinguished by the specific cytokines they produce. TH1-type cytokines lead
to pro-inflammatory responses and while they participate in the initiation of
autoimmune responses, they are protective later in disease. TH2-type cytokines
are important in immunoglobulin production and predominate in later disease
(22).
Experiments on male estrogen receptor knockout mice that were
administered estrogen showed that the shifts from TH2 to TH1 responses were
protective while a TH2 response exacerbated autoimmune disease (16-21). These
results suggested that estrogen has a differential effect in promoting TH1 and TH2
responses, as well as raise the question of the importance of the ER in inducing
these responses. Consequently, the hypothesis that was tested in this project was
that exposure to estrogen will lead to modulation of immune cells though an
interaction with the specific ERs that they express. This hypothesis was tested by
exposing male ERα, ERβ and ERαβ knockout chimeric mice to chronic doses of
estrogen with the aims of identifying the consequences of estrogen exposure in
the numbers and functions of immune cells, to determine whether these
modulations resulted from the interaction of estrogen and its receptors.

Methods

Thirty C57 Black 6 (C57BL/6) male mice were irradiated with a total of
1100 rads. The day after irradiation, the mice were reconstituted with cells from
donor bone marrow prepared from either of four types of male estrogen receptor
(ER)-deficient mice: wild type (WT), alpha knockout (αERKO), beta knockout
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(βERKO) or double knockout (αβERKO or KO/KO) for the ER. Donor cells
were prepared from 2-3 mice of the appropriate ER genotype, which were
euthanized by CO2 asphyxiation. Their femurs and tibias were removed and all
muscle was removed from the bones. The ends were cut off and the bone marrow
was flushed out. The marrow was flushed into another dish containing and the
clumps were broken. The mixture was then spun down and suspended in media.
Groups of seven irradiated recipient mice were reconstituted the appropriate
donor cell type. Two mice served as controls for irradiation and were not
reconstituted and within ten days of irradiation, these mice were moribund. This
confirmed that the lethal irradiation was successful.
Seven weeks after reconstitution, four mice from each group were injected
estrogen in oil and three mice were injected with oil vehicle by subcutaneous
injection between the shoulder blades. These injections were performed
subsequently every month (4 weeks) for 5 months. Body weights were measured
before each injection. In order to study the effect of this estrogen treatment on
immunity and specifically the production of cytokines and immunoglobulin, the
mice were euthanized and their cells were harvested. We performed an enzymelinked immunosorbent assay (ELISA) on these cells suspensions.
Project Significance

As aforementioned, much has yet to be understood about the mechanisms
through with the sex hormone modulates autoimmune disease. Various autoimmune
diseases, including lupus and rheumatoid arthritis have been shown to modulate in their
clinical manifestation according to levels of estrogen. In fact, in addition to the gender
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bias, lupus is also seen to manifest itself predominantly in women in child-bearing age. In
light of this, the current project provides further evidence that estrogen plays a

critical role in triggering the development of autoimmune lupus nephritis through
its effect on cytokine production, since in general we saw an increase in TH2
cytokines, leading to activation of B cells and the production of auto-antibodies,
with estrogen treatment. We also observed an increase in TH1 cytokine IFN-γ
which is thought to play an important role in initiating autoimmune disease.
Results from estrogen receptor knockout mice also provided evidence that both
estrogen receptor subtypes, ER-α and ER-β, play significant roles in the
autoimmunity disease cytokine and immunoglobulin profile. Our results also
suggested that ER-α might have a more significant effect.
These findings support a role for estrogen and ER in the increased
incidence of autoimmune diseases in females. This study is significant in light of
the growing use of estrogen in contraceptive, hormone replacement therapy and
various dietary supplements nowadays. It is important for individuals who have
been diagnosed with autoimmune disease to learn more about their condition and
the mechanisms involved in order to better manage and cope with it. Furthermore,
the findings from this project and others have been conducted in the field serve to
open new avenues for the devising therapeutic agent that will specifically target
the different mechanisms involved in autoimmune disease manifestation and
progression.

